

UCSF

UC San Francisco Previously Published Works

Title

Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes

Permalink

<https://escholarship.org/uc/item/8138h26s>

Journal

Cell Host & Microbe, 28(1)

ISSN

1931-3128

Authors

Osuna, Beatriz A
Karambelkar, Shweta
Mahendra, Caroline
[et al.](#)

Publication Date

2020-07-01

DOI

10.1016/j.chom.2020.04.001

Peer reviewed



Published in final edited form as:

Cell Host Microbe. 2020 July 08; 28(1): 31–40.e9. doi:10.1016/j.chom.2020.04.001.

Listeria phages induce Cas9 degradation to protect lysogenic genomes

Beatriz A. Osuna¹, Shweta Karambelkar¹, Caroline Mahendra¹, Kathleen A. Christie^{2,3,4}, Bianca Garcia⁵, Alan R. Davidson^{5,6}, Benjamin P. Kleinstiver^{2,3,4}, Samuel Kilcher⁷, Joseph Bondy-Denomy^{1,8,9,10,*}

¹Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA ²Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA ³Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA ⁴Department of Pathology, Harvard Medical School, Boston, MA 02115, USA ⁵Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 1M1, Canada ⁶Department of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, Canada ⁷Institute of Food, Nutrition, and Health, ETH Zurich, Zurich CH 8092, Switzerland ⁸Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA ⁹Innovative Genomics Institute ¹⁰Lead Contact

SUMMARY

Bacterial CRISPR-Cas systems employ RNA-guided nucleases to destroy phage (viral) DNA. Phages, in turn, have evolved diverse “anti-CRISPR” proteins (Acrs) to counteract acquired immunity. In *Listeria monocytogenes*, prophages encode 2–3 distinct anti-Cas9 proteins, with *acrIIA1* always present. However, the significance of AcrIIA1s pervasiveness and its mechanism are unknown. Here, we report that AcrIIA1 binds with high affinity to Cas9 via the catalytic HNH domain. During lysogeny in *Listeria*, AcrIIA1 triggers Cas9 degradation, but during lytic infection, AcrIIA1 fails to block Cas9 due to its multi-step inactivation mechanism. Thus, phages require an additional Acr that rapidly binds and inactivates Cas9. AcrIIA1 also uniquely inhibits a highly-diverged Cas9 found in *Listeria* (similar to SauCas9) and Type II-C Cas9s, likely due to Cas9 HNH domain conservation. In summary, *Listeria* phages inactivate Cas9 in lytic growth

*Correspondence: joseph.bondy-denomy@ucsf.edu.

AUTHOR CONTRIBUTIONS

B.A.O. and J.B.-D. conceived and designed the study. B.A.O., S.Ka., C.M., K.A.C., B.G., and S.Ki. performed experiments. A.R.D., B.P.K., S.Ki., and J.B.-D. supervised experiments. All authors evaluated results. B.A.O. and J.B.-D. wrote the manuscript with input from all authors.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DECLARATION OF INTERESTS

J.B.-D. is a scientific advisory board member of SNIPR Biome and Excision Biotherapeutics and a scientific advisory board member and co-founder of Acrigen Biosciences, and is an inventor on patents relating to anti-CRISPR proteins. B.P.K. is an inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies, is a consultant for Avectas Inc., and an advisor to Acrigen Biosciences. A.R.D. is a scientific advisory board member for Acrigen Biosciences and is an inventor on patents relating to anti-CRISPR proteins.

using variable, narrow-spectrum inhibitors, while the broad-spectrum AcrIIA1 stimulates Cas9 degradation for protection of the lysogenic genome.

Graphical Abstract



eTOC

Bacteriophages inactivate CRISPR-Cas immunity by encoding “anti-CRISPR” proteins. Osuna et al. reveal that a protein commonly encoded by *Listeria* phages, AcrIIA1, directly binds to the Cas9 HNH domain and stimulates its degradation to stabilize the lysogenic state, while the phages use an independent Acr protein for lytic replication.

INTRODUCTION

All cells must combat viral infections to survive. Bacteria have evolved innate and adaptive defense mechanisms against bacterial viruses (phages), which constantly pose a risk of infection. One such defense mechanism is CRISPR-Cas, a common and diverse adaptive immune system in prokaryotes that encompasses two distinct classes and six types (I-VI) (Koonin et al., 2017; Makarova et al., 2015). The CRISPR array maintains a genetic record of past viral infections with phage DNA fragments (spacers) retained between clustered regularly interspaced short palindromic repeats (CRISPR) (Mojica et al., 2005). These phage-derived spacers are transcribed into CRISPR RNAs (crRNAs) that complex with Cas nucleases to guide the sequence-specific destruction of invading nucleic acids (Brouns et al.,

2008; Garneau et al., 2010). The CRISPR-associated (cas) genes typically neighbor the CRISPR array and encode proteins that facilitate spacer acquisition into the CRISPR array (Nuñez et al., 2014; Yosef et al., 2012), generate mature crRNAs (Deltcheva et al., 2011; Haurwitz et al., 2010), and cleave invading genomes (Garneau et al., 2010).

To counteract bacterial immunity, phages have evolved multiple mechanisms of CRISPR-Cas evasion (Borges et al., 2017). Phage-encoded anti-CRISPR proteins have been shown to directly inhibit the type I-C, I-D, I-E, I-F, II-A, II-C, III-B, and V-A CRISPR-Cas systems (Hwang and Maxwell, 2019; Trasanidou et al., 2019), and they all have distinct protein sequences, structures, and mechanisms. Some anti-CRISPRs such as AcrIIA2 and AcrIIA4, encoded by *Listeria* phages, block CRISPR-Cas target DNA binding by steric occlusion and DNA mimicry (Bondy-Denomy et al., 2015; Dong et al., 2017; Jiang et al., 2019; Liu et al., 2019), while others interfere with guide-RNA loading (Thavalingam et al., 2019; Zhu et al., 2019), induce effector dimerization (Fuchsbaauer et al., 2019; Harrington et al., 2017; Zhu et al., 2019), or prevent DNA cleavage by interacting with the catalytic domains of Cas nucleases (Bondy-Denomy et al., 2015; Harrington et al., 2017). Type II CRISPR-Cas systems have been widely investigated for genome editing applications. However, few studies have examined Cas9-anti-CRISPR interactions in the natural context of phage-bacteria warfare (Hynes et al., 2017, 2018).

In the lytic cycle, phage replication causes host cell lysis, whereas in lysogeny, temperate phages integrate into the bacterial chromosome and become prophages. The bacterial host and prophage replicate together during lysogeny and prophages can contribute novel genes that provide fitness benefits or even serve as regulatory switches (Argov et al., 2017; Bondy-Denomy et al., 2016; Feiner et al., 2015; Rabinovich et al., 2012). In *Listeria monocytogenes*, prophages inactivate CRISPR-Cas9 through the expression of anti-CRISPR proteins (Rauch et al., 2017). In lysogens with CRISPR arrays encoding spacers that target the prophage (i.e. self-targeting), anti-CRISPRs are essential for host and prophage survival. However, whether anti-CRISPRs play distinct roles during lysogeny or lytic growth when expressed by temperate phages is unknown.

Here, we show that the *Listeria* phage protein AcrIIA1 selectively triggers degradation of catalytically active Cas9, through a direct interaction between the AcrIIA1^{CTD} (C-terminal domain) unstructured loop and Cas9 HNH domain. AcrIIA1 is sufficient to prevent CRISPR-targeting of prophages, but is ineffective during lytic replication due to its multi-step Cas9 inactivation mechanism. This latter property necessitates the co-existence of AcrIIA1 with an anti-CRISPR (e.g. AcrIIA2, AcrIIA4, or AcrIIA12, identified here) that rapidly binds and simultaneously blocks Cas9 during lytic infection.

RESULTS

AcrIIA1 specifically induces degradation of catalytically active Cas9

To determine the AcrIIA1 mechanism of action, we first attempted to immunoprecipitate Cas9 from *L. monocytogenes* (*Lmo10403s*) strains where AcrIIA1 was expressed from one of three prophages (Φ A006, Φ A118, and Φ J0161a). Surprisingly, upon immunoblotting for Cas9 protein, we observed highly reduced Cas9 levels in these lysogens (Figure 1A, top).

Cas9 transcriptional and translational reporters revealed that transcript levels were unaffected, while the protein reporter levels decreased by ~70% (Figure 1A, bottom). RT-qPCR experiments confirmed *cas9* mRNA levels were unaffected in each lysogen (Figure S1A). AcrIIA1 alone, but not AcrIIA4, was sufficient to mediate decreased Cas9 levels in both the immunoblotting (Figure 1B, top) and reporter assays (Figure 1B, bottom left and S1B). The well-studied orthologue, SpyCas9 (53% amino acid identity to LmoCas9), displayed the same post-transcriptional AcrIIA1-dependent loss of Cas9 when introduced into *L. monocytogenes* (Figure 1B, bottom right and S1B). To test whether AcrIIA1 stimulates Cas9 degradation post-translationally, we measured the stability of SpyCas9 protein in *L. monocytogenes*. Upon induction of AcrIIA1, we observed an accelerated decay of SpyCas9 protein in comparison to treatment with a translation inhibitor, gentamicin (Figures 1C and S1C). In contrast, SpyCas9 protein increased over time when AcrIIA1 was not induced, similar to strains expressing AcrIIA4 or lacking an anti-CRISPR (Figures 1C and S1C). Thus, Cas9 degradation is specifically triggered by AcrIIA1 and is not a general consequence of Cas9 inhibition by any anti-CRISPR.

Given that AcrIIA1 induces Cas9 degradation, we expected that this anti-CRISPR would inhibit catalytically-dead Cas9 (dCas9) in a *Listeria* CRISPRi assay. However, we observed that AcrIIA1 did not inhibit Lmo- or Spy- dCas9 engineered to repress RFP expression (Figures 2A and S2A), but did inhibit active Cas9 in an isogenic self-targeting strain (Figure 2B). Consistent with these findings, lysogens expressing AcrIIA1 or AcrIIA4 alone or together also revealed no significant decrease in dCas9 levels, whereas active Cas9 protein diminished by ~70% in all AcrIIA1-expressing lysogens (Figures 2C, S2B and S2C). Therefore, AcrIIA1 has a mechanism to detect catalytically active Cas9 protein and induce its degradation.

AcrIIA1 binds directly to Cas9 via the catalytic HNH domain

Due to the discrepant inhibition of Cas9 and dCas9 by AcrIIA1, we assessed the ability of AcrIIA1 to bind these proteins *in vitro* using microscale thermophoresis (MST). AcrIIA1 and SpyCas9-gRNA (SpyCas9 was used because LmoCas9 was insoluble) interacted with high affinity ($K_D = 23 \pm 15$ nM), comparable to AcrIIA2b.3 ($K_D = 20 \pm 11$ nM, Figure 2D), a well-characterized Cas9-interactor (Jiang et al., 2019). AcrIIA1 co-purified with RNA, as seen previously (Ka et al., 2018) however, benzonase treatment to remove nucleic acids did not impact the binding affinity (data not shown). Only two residues differ between catalytically active Cas9 and dCas9 (D10A and H840A). AcrIIA1 binding to dCas9 and Cas9(H840A) was reduced ~40-fold ($K_D = 905 \pm 874$ nM) and ~80-fold ($K_D = 2 \pm 4$ μ M) respectively, whereas binding to Cas9(D10A) ($K_D = 38 \pm 30$ nM) was similar to wild-type Cas9 (Figure 2D). AcrIIA2b.3, which binds the PAM-interacting domain, displayed no difference in binding affinity to the four Cas9 variants ($K_D = 18 - 38$ nM, Figure S2D). These results were consistent with an *in vitro* pull-down assay using the four Cas9 variants and AcrIIA1 or AcrIIA2b.3 (Figure S2E). Additionally, AcrIIA1 interacted well with ApoCas9 ($K_D = 18 \pm 7$ nM, Figure S2F), Cas9-gRNA prebound to a DNA substrate ($K_D = 31 \pm 22$ nM, Figure S2G), and Cas9-gRNA prebound to AcrIIA2b.3 ($K_D = 24 \pm 16$ nM, Figure S2H), demonstrating a unique binding mechanism for AcrIIA1. Interestingly, AcrIIA1 binding *in vitro* was not sufficient to degrade Cas9 or destabilize it when subjected

to limited proteolysis (Figure S2I), nor did AcrIIA1 inhibit DNA cleavage by Cas9 (Figure 2E). Thus, we conclude that AcrIIA1 directly interacts with the catalytic Cas9 HNH domain (where H840 resides), but requires an additional stimulus, presumably provided by the *L. monocytogenes* cellular environment, that activates Cas9 degradation (see Discussion).

AcrIIA1 protects CRISPR-targeted prophages but fails during lytic replication

We next sought to determine when AcrIIA1 anti-CRISPR activity manifests during the phage life cycle. Isogenic Φ A006 phages were engineered to encode no anti-CRISPR, *acrIIA1*, *acrIIA4*, or *acrIIA1* and *acrIIA4* together, and assessed along with wild-type (WT) phage, during lytic infection (Figure 3A) and lysogenic replication (Figure 3B). When infecting *Lmo10403s* expressing Cas9 and a native Φ A006-targeting spacer sequence, phages encoding only *acrIIA1* surprisingly failed to replicate, similar to a *acr* phage (efficiency of plaquing, EOP $\approx 3 \times 10^{-5}$, Figures 3A and S3A). Phages encoding *acrIIA4* replicated well (EOP = 0.1 – 0.7, depending on *acrIIA4* expression strength), similar to WT Φ A006 (EOP ≈ 0.7), with no added benefit derived from *acrIIA1* (Figures 3A and S3A). In contrast, after the establishment of lysogeny, *acrIIA1* was sufficient for prophage survival. Φ A006 prophages encoding only *acrIIA1* completely prevented self-targeting when WT Cas9 was induced, whereas lysogens lacking an anti-CRISPR (*acr*) died (Figure 3B). These data suggest that AcrIIA1 is optimal for lysogeny, but ineffective during lytic infection (where phage DNA is rapidly cleaved), perhaps due to the additional rate-limiting stimulus required to induce degradation after AcrIIA1 binds Cas9 (see Discussion).

The inability of AcrIIA1 to independently inhibit Cas9 during lytic infection, suggests that phages need additional Cas9 inhibitors to establish lysogeny. In 119 *Listeria* prophage genomes analyzed, 77% encode *acrIIA1* with at least one additional *acrIIA* gene (i.e. *acrIIA2-A4*), 13% possess *acrIIA1* without a known *acrIIA* neighbor (including WT Φ A006), and 10% encode *orfD* (a distant *acrIIA1* orthologue) (Rauch et al., 2017). The WT Φ A006 phage, which has *acrIIA1* and no other known *acr*, replicated far better (EOP ≈ 0.7) than an engineered phage encoding *acrIIA1* alone, suggesting an additional Cas9 inhibitor in this phage (Figures 3A and S3A). Engineered phages encoding the gene adjacent to *acrIIA1* restored phage lytic replication (EOP ≈ 0.5 , Figures 3A and S3A) and revealed anti-CRISPR, AcrIIA12, which also inhibited Lmo (but not Spy) dCas9-based CRISPRi (Figure S3B). Notably, we observed the presence of *acrIIA12* in every *acr* locus previously reported to encode only *acrIIA1*, indicating that phages do not encode *acrIIA1* alone. Therefore, *Listeria* prophages most commonly encode *acrIIA1*, which triggers Cas9 degradation to ensure stable lysogeny, in combination with a Cas9 interactor that blocks DNA binding (AcrIIA2, AcrIIA4, or AcrIIA12) for successful lytic replication.

AcrIIA1 utilizes an unstructured C-terminal loop to inactivate Cas9

The AcrIIA1 crystal structure revealed a two-domain architecture, with a helix-turn-helix (HTH)-containing AcrIIA1^{NTD} similar to known transcriptional repressors and an extended AcrIIA1^{CTD} of unknown function (Ka et al., 2018). Surprisingly, AcrIIA1^{CTD} was both necessary and sufficient for anti-CRISPR function, protecting *Listeria* cells from self-targeting (Figure S3C) and inducing Cas9 protein degradation (Figures S3D and S3E). The AcrIIA1^{NTD} displayed no evidence of CRISPR-Cas9 inhibition or regulation (Figures S3C

and S3D), and is instead required for autoregulation of the phage *anti-CRISPR* locus (see companion manuscript; Osuna et al., 2020b). To further characterize the AcrIIA1 mechanism of Cas9 inactivation, AcrIIA1 homologs were tested in our *P. aeruginosa* anti-SpyCas9 screening platform (Jiang et al., 2019) and sequence conservation was used to guide the construction of mutants. First, we confirmed that similar to in *Listeria*, AcrIIA1_{ΦA006} displayed robust inhibition of active Cas9 in *P. aeruginosa* (Figure S4A, left) and did not interfere with dCas9 (Figure S4A, right). The AcrIIA1 homologs tested for Cas9 inhibition were identified in mobile genetic elements of *Listeria*, *Enterococcus*, *Lactobacillus*, and *Leuconostoc* species, with protein sequence identity ranging from 22% to 77% (Figure 4A). As expected, only homologs with conserved CTDs displayed anti-SpyCas9 activity, whereas the three proteins with highly diverged CTDs (including *orfD*) did not (Figures 4B and S4B). Alanine scanning mutagenesis of amino acids conserved across the AcrIIA1 homologs identified a stretch of aromatic and charged residues in an unstructured region of the AcrIIA1^{CTD} (P112 to R117) that were required for complete anti-CRISPR activity (Figures 4C and S4B). Expression levels of each mutant protein were unperturbed relative to WT AcrIIA1 (Figure S4C). Notably, the AcrIIA1(F115A) and AcrIIA1(T114A/F115A) mutants completely lost anti-CRISPR function (Figures 4C and S4B), and very weakly interacted with Cas9 *in vitro* (Figures S4D). In *Listeria*, these same mutants failed to protect cells from genomic self-targeting (Figure S3C) and completely (T114A/F115A) or partially (F115A) lost the ability to induce Cas9 protein degradation (Figure S3E). Thus, AcrIIA1 uses highly conserved residues in its CTD to interact with the Cas9 HNH domain and trigger Cas9 protein degradation in *Listeria*.

Cas9 inactivation by AcrIIA1 is a multi-step process

To determine if AcrIIA1 mutants differentially impact Cas9 protein levels, immunoblots were performed, surprisingly revealing that wild-type AcrIIA1 can inhibit Cas9 in *P. aeruginosa* without triggering its degradation (Figure S4C). When immunoprecipitated from this heterologous host, Cas9 co-purified with AcrIIA1 or the control AcrIIA4 (Figure 4D) and these complexes failed to cleave DNA (Figure 4E), whereas Cas9-gRNA alone or Cas9 bound to AcrIIA1(F115A) and AcrIIA1(T114A/F115A) was functional (Figures 4E, S4E and S4F). No other proteins stoichiometrically co-immunoprecipitated with Cas9-AcrIIA1 (Figure S4G), suggesting that inhibition *in vivo* does not require an additional stable protein interactor. Thus, AcrIIA1 inhibits Cas9 using a multi-step mechanism that first involves a high affinity interaction, a subsequent inhibited state locked in by the cellular environment (seen *ex vivo* in Figure 4E, but *not* recapitulated *in vitro* in Figure 2E), and finally Cas9 degradation mediated by an additional *Listeria*-specific stimulus. The non-native host *P. aeruginosa* apparently lacks this Cas9-degrading pathway. This multi-step inactivation mechanism likely explains the inefficiency of AcrIIA1 during phage lytic infection and the necessary co-existence with another anti-CRISPR that rapidly binds and directly inactivates Cas9 in a single-step process (a mechanism that *is* recapitulated *in vitro* in Figure 2E).

AcrIIA1 is a broad-spectrum Cas9 inhibitor

Listeria species also contain a highly diverged Type II-A Cas9 (LivCas9, 1,078 a.a., Hupfeld et al., 2018), which shares similarities with other small Cas9 proteins (e.g. SauCas9) and Type II-C orthologues (Figure 5A). The AcrIIA1 Cas9 inactivation mechanism, which

involves recognition of a highly conserved catalytic residue (H840), suggested it might inhibit diverged Cas9 orthologues. Indeed, AcrIIA1 inhibited LivCas9 in *Listeria* strains programmed to target phage Φ P35 or Φ A511, while AcrIIA4 and AcrIIA12 failed to inhibit (Figures 5B and S5A). To ascertain the extent of AcrIIA1s spectrum of inhibition, we tested *Escherichia coli* strains expressing Type II-A, II-B, and II-C Cas9 proteins targeting phage Mu. AcrIIA1 intermediately or completely inhibited four Type II-C (Geo, Cje, Hpa, and Boe) and two Type II-A (Sau and Spy) Cas9s (Figures 5C and S5B). In contrast, AcrIIA2 only weakly inhibited Hpa and SpyCas9, and AcrIIA4 only inactivated SpyCas9 (Figure 5C). Thus, AcrIIA1 displays broad-spectrum activity against diverged Cas9 nucleases, which further explains the utility of AcrIIA1 to phages infecting *Listeria*, where at least two distinct Cas9 orthologues are encountered.

The robust AcrIIA1 activity observed in various heterologous hosts led us to assess inhibition of Cas9 gene editing in human cells. We employed a deep sequencing-based approach to improve the dynamic range of edit detection, in comparison to our previous GFP-disruption assay (Rauch et al., 2017). HEK 293T cells were co-transfected with plasmids encoding *acrIIA1*, *cas9*, and sgRNAs targeting endogenous human sequences and editing efficacy was evaluated after 3 days. AcrIIA1 blocked the gene editing activity of SpyCas9 by 50–70% and of CjeCas9, SauCas9, St3Cas9, and NmeCas9 by 20–40%, whereas AcrIIA4 only inhibited SpyCas9 (Figures 5D and S5C). Titration of anti-CRISPR expression plasmids over a range of concentrations confirmed that AcrIIA1 was a less potent inhibitor than cognate Acrs for SpyCas9 and CjeCas9 (Figure S5D). However, these experiments also revealed that AcrIIA1^{CTD} alone is more effective than full-length AcrIIA1, and as expected the AcrIIA1(T114A/F115A) double mutant was inactive (Figure S5D). Thus, AcrIIA1 inactivates diverse Cas9 orthologues in many heterologous systems, including bacteria (*L. monocytogenes*, *P. aeruginosa*, *E. coli*), yeast (Nakamura et al., 2019), and human cells, providing a genome editing modulator that specifically inhibits active Cas9, but not deadCas9. Future work is needed to enhance its efficiency, however. Our attempts to increase anti-CRISPR function in human cells by weakening DNA interactions with the T16A mutation or AcrIIA1^{NTD} removal (companion manuscript; Osuna et al., 2020b) were only modestly successful (Figures 5D, S5C and S5D). Future engineering of AcrIIA1 could generate a more potent inhibitor, as recently achieved with AcrIIC1 (Mathony et al., 2019).

DISCUSSION

Listeria temperate phages commonly encode the multifunctional AcrIIA1 protein for protection against CRISPR-Cas and autorepression of anti-CRISPR transcription (companion manuscript; Osuna et al., 2020b). The broad-spectrum AcrIIA1 is sufficient for maintaining Cas9 inactivation after lysogeny has been established, but is nonfunctional during lytic growth, likely due to the multi-step inactivation mechanism that first requires Cas9 binding, a second rate-limiting step that leads to inhibition, and lastly, Cas9 degradation. Cas9 has been shown to cleave phage DNA in as little as 2 min post-infection (Garneau et al., 2010). Thus, a distinct anti-Cas9 protein (e.g. AcrIIA2, AcrIIA4, AcrIIA12) that is much narrower in its inhibitory spectrum, but uses a one-step mechanism to rapidly bind and inactivate Cas9, coexists with AcrIIA1 to allow lytic replication and the initial

establishment of lysogeny. Although AcrIIA4 and AcrIIA12 also protect CRISPR-targeted prophages, only AcrIIA1 triggers Cas9 degradation. *Listeria* lysogens were devoid of Cas9 protein even when *acrIIA1* was co-encoded with other *acrs*, supporting that Cas9 degradation is the dominant inactivation mechanism in lysogeny. Given that Cas9 is required for the acquisition of functional new spacers (Heler et al., 2015), eliminating it could also prevent acquisition of lethal self-targeting spacers. Altogether, these data suggest *Listeria* temperate phages employ a “division of labor” approach, evolving multiple *Acrcs* with distinct Cas9 binding sites and inactivation mechanisms because they synergistically grant unique advantages in the temperate phage life cycle and together ensure long-term stability in lysogeny (see Graphical Abstract).

Much remains to be elucidated about AcrIIA1’s mechanism of action. Given that AcrIIA1 binds both ApoCas9 and gRNA-bound Cas9 and co-purifies with RNA (our observations and Ka et al., 2018), AcrIIA1 may also impact gRNA biogenesis or loading. While previous work (Ka et al., 2018) ruled out direct interactions between AcrIIA1 and CRISPR-Cas nucleic acids *in vitro* (e.g. tracrRNA, crRNA, tracrRNA:crRNA duplex), AcrIIA1 bound to ApoCas9 may occlude gRNA processing or loading. We were unable to directly test this possibility as recombinantly-purified AcrIIA1 protein lacks inhibition or degradative activity *in vitro*, even when preincubated with ApoCas9. While we demonstrate that AcrIIA1 triggers degradation of pre-expressed Cas9-gRNA *in vivo* (Figure 1C), it is possible that AcrIIA1 may also destabilize ApoCas9 directly or by preventing loading, similar to AcrIIC2, a Type II-C inhibitor that blocks gRNA loading (Thavalingam et al., 2019; Zhu et al., 2019).

We also observed many parallels between AcrIIA1 and AcrIIC1, another Type II-C Cas9 inhibitor. AcrIIC1 binds to the Cas9 HNH domain with strong affinity ($K_D = 6.3$ nM; Harrington et al., 2017), but is a rather weak anti-CRISPR in comparison to AcrIIC3–5 (Lee et al., 2018; Mathony et al., 2019). In contrast to the narrow-spectrum DNA binding inhibitors AcrIIC3–5, AcrIIC1 blocks a broad spectrum of Type II-C orthologues by directly binding Cas9 (Apo or gRNA-bound) via the HNH domain (Harrington et al., 2017). Similarly, AcrIIA1 also targets the highly conserved Cas9 HNH domain catalytic site, likely explaining its capacity to inhibit a broad-spectrum of Cas9 orthologues in comparison to the narrow-spectrum DNA binding inhibitors AcrIIA2, AcrIIA4, AcrIIA12. This AcrIIA1 feature provides a unique advantage to *Listeria* phages, allowing inhibition of a small LivCas9 variant (25% amino acid identity to large LmoCas9) that is also found in *L. monocytogenes* strains. Thus, Cas9 HNH-domain interactors may tend to be weaker anti-CRISPRs, but they considerably bolster the phage defense arsenal by targeting a highly conserved, and potentially immutable feature amongst bacterial Cas nucleases.

STAR METHODS

RESOURCE AVAILABILITY

Lead Contact—Please direct any requests for further information or reagents to the lead contact, Joseph Bondy-Denomy (joseph.bondy-denomy@ucsf.edu).

Materials Availability—*Listeria* strains, plasmids, and phages constructed and used in this study are disclosed in Table S2 (Excel spreadsheet). Nuclease, sgRNA, and Acr plasmids used in human cell experiments are disclosed in Table S3 (Excel spreadsheet). Oligonucleotides used in human cell experiments are disclosed in Table S4 (Excel spreadsheet).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Microbe Strains—*Listeria monocytogenes* strains (10403s) were cultured in brain-heart infusion (BHI) medium at 30°C. All *Lmo* strains containing pPL2oexL-Rhamnose-inducible constructs were cultured in Luria broth (LB) supplemented with 50–150 mM glycerol (neutral carbon source; no induction/repression) and 0–100 mM rhamnose (inducer) as indicated. To ensure plasmid maintenance in *Listeria* strains, BHI or LB was supplemented with tetracycline (2 µg/mL) for the pPL2oexL integrated construct or erythromycin (7.5 µg/mL) for pLEB579. *Escherichia coli* (DH5α, XL1Blue, NEB 10-beta, or NEB Turbo for plasmid maintenance and SM10 for conjugation into *Listeria*) and *Pseudomonas aeruginosa* (PAO1) were cultured in LB medium at 37°C. To maintain plasmids, LB was supplemented with chloramphenicol (25 µg/mL) for pPL2oexL in *E. coli*, erythromycin (250 µg/mL) for pLEB579 in *E. coli*, gentamicin (30 µg/mL) for pHERD30T in *E. coli* and *P. aeruginosa*, or carbenicillin (250 µg/mL for *P. aeruginosa*, 100 µg/mL for *E. coli*) for pMMB67HE. For maintaining pHERD30T and pMMB67HE in the same *P. aeruginosa* strain, media was supplemented with 30 µg/mL gentamicin and 100 µg/mL carbenicillin. *Listeria* strains, plasmids, and phages constructed and used in this study are listed in Table S2.

Phages—*Listeria* phages A006, A118, J0161a, and their derivatives were all propagated at 30°C on *acrIIA1^{NTD}*-expressing *L. monocytogenes* 10403sϕcure (*cas9*, *tRNA^{Arg}::pPL2oexL-acrIIA1^{NTD}*) to allow optimal lytic growth of phages lacking their own *acrIIA1^{NTD}*. A511 was propagated on *L. ivanovii* WSLC 3009 at 30°C and P35 on *L. monocytogenes* Mack at 20°C. The *Pseudomonas* DMS3m-like phage (JBD30) was propagated on PAO1 at 37°C. All phages were stored in SM buffer (100 mM NaCl, 8 mM MgSO₄•7H₂O, 50 mM Tris-HCl pH 7.5, 0.01% (w/v) gelatin), supplemented with 10 mM CaCl₂ for *Listeria* phages, at 4°C.

Human cell lines—Human HEK 293T cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated FBS (HI-FBS) and 1% penicillin/streptomycin. Media supernatant from cell cultures was analyzed monthly for the presence of mycoplasma using MycoAlert PLUS (Lonza).

METHOD DETAILS

***Listeria* phage titering**—A mixture of 150 µL stationary *Listeria* culture and 3 mL molten LC top agar (10 g/L tryptone, 5 g/L yeast extract, 10 g/L glucose, 7.5 g/L NaCl, 10 mM CaCl₂, 10 mM MgSO₄, 0.5% agar) was poured onto a BHI plate (1.5% agar) to generate a bacterial lawn, 3 µL of phage ten-fold serial dilutions were spotted on top, and after 24 hr incubation at 30°C, plate images were collected using the Gel Doc EZ Documentation system (BioRad) and Image Lab (BioRad) software.

Construction of *Lmo10403s* lysogens—Lysogens were isolated from plaques that emerged after titrating phages ϕ A006, ϕ A118, ϕ J0161a, and their derivatives on a lawn of *Lmo10403s* ϕ cure *cas9* (see “*Listeria* phage titering”). Lysogeny was confirmed by prophage induction with mitomycin C (0.5 μ g/mL) treatment as previously described (Estela et al., 1992) and by PCR amplification and Sanger sequencing of the phage anti-CRISPR locus. All *Lmo10403s* strains containing prophages were lysogenized and verified prior to introducing additional constructs (integrated pPL2oexL).

***Listeria* and *Pseudomonas* strain construction**—DNA fragments were PCR-amplified from genomic, plasmid, or synthesized DNA and cloned by Gibson Assembly into *Listeria* plasmids: episomal pLEB579 (Beasley et al., 2004) or the pPL2oexL single-copy integrating plasmid derived from pPL2 (Lauer et al., 2002) or *P. aeruginosa* plasmids: pMMB67HE or pHERD30T. To generate all *Listeria* strains, pPL2oexL plasmids were conjugated (Lauer et al., 2002; Simon et al., 1983) and pLEB579 plasmids were electroporated (Hupfeld et al., 2018; Park and Stewart, 1990) into *Lmo10403s*. For all *Pseudomonas* strains, plasmids were electroporated into PAO1 (Choi et al., 2006).

***Listeria* protein samples for immunoblotting**—Saturated overnight cultures of *Lmo10403s* strains overexpressing FLAG-tagged Cas9 (*cas9*, *tRNA^{Arg}::pPL2oexL-LmoCas9-6xHis-FLAG*) were diluted 1:10 in BHI with appropriate antibiotic selection (see “microbes”), grown to log phase (OD₆₀₀ 0.2–0.6), harvested by centrifugation at 8000 g for 5 min at 4°C, and lysed by bead-beating or lysozyme treatment. For bead-beating: 4 OD₆₀₀ units of each culture were harvested, cell pellets were resuspended in 500 μ L ice cold lysis buffer (50 mM Tris-HCl pH 8.0, 650 mM NaCl, 10 mM MgCl₂, 10% glycerol, 1x cComplete mini EDTA-free protease inhibitor cocktail [Roche]), combined with ~150 μ L 0.1 mm glass beads, and vortexed for 1 hr at 4°C. Cell debris was cleared by centrifugation at 21000 g for 5 min at 4°C and supernatant was mixed with one-third volume 4X Laemmli Sample Buffer (Bio-Rad). For lysozyme lysis: 1.6 OD₆₀₀ units were harvested, cell pellets were resuspended in 200 μ L of TE buffer supplemented with 2.5 mg/mL lysozyme and 1x cComplete mini EDTA-free protease inhibitor cocktail (Roche), samples were incubated at 37°C for 30 min, quenched with one-third volume of 4X Laemmli Sample Buffer (Bio-Rad), and boiled for 5 min at 95°C.

Immunoblotting—Protein samples were separated by SDS-PAGE using 4–20% Mini-PROTEAN TGX gels (Bio-Rad) and transferred in 1X Tris/Glycine Buffer onto 0.22 micron PVDF membrane (Bio-Rad). Blots were probed with the following antibodies diluted 1:5000 in 1X TBS-T containing 5% nonfat dry milk: rabbit anti-FLAG (Sigma-Aldrich Cat# F7425, RRID:AB_439687), mouse anti-FLAG (Sigma-Aldrich Cat# F1804, RRID:AB_262044), mouse anti-Myc (Cell Signaling Technology Cat# 2276, RRID:AB_331783), rabbit anti-GST (Cell Signaling Technology Cat# 2625, RRID:AB_490796), mouse anti-*E.coli* RNA polymerase β (BioLegend Cat# 663903, RRID:AB_2564524), HRP-conjugated goat anti-Rabbit IgG (Bio-Rad Cat# 170–6515, RRID:AB_11125142), and HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology Cat# sc-2005, RRID:AB_631736). Blots were developed using Clarity ECL Western Blotting Substrate (Bio-Rad) and chemiluminescence was detected on an Azure c600 Imager (Azure Biosystems).

Bacterial growth & fluorescence measurements—Saturated overnight cultures were diluted 1:100 in 150 μ L BHI or LB media with appropriate antibiotic selection (see “microbes”) in a 96-well special optics microplate (Corning). *Listeria* cells were incubated at 30°C and *Pseudomonas* at 37°C with continuous double-orbital rotation for 16–48 hr in the Synergy H1 Hybrid Multi-Mode Reader (BioTeK) and measurements of OD₆₀₀ and mCherry (excitation 570 nm, emission 610 nm) relative fluorescence units (RFU) recorded every 5 min with the Gen5 (BioTek) software. For bacterial growth curves, data are displayed as the mean OD₆₀₀ of at least three biological replicates \pm SD (error bars) as a function of time (min or hr, as indicated). For Cas9-mCherry or mCherry fluorescence levels, background fluorescence of growth media was subtracted and the resulting RFU values were normalized to OD₆₀₀ for each time point. Data are displayed as the mean normalized fluorescence ($\frac{RFU - background}{OD_{600}}$) of three biological replicates \pm SD.

Cas9 protein and mRNA reporter quantification—Cas9 (WT or dead; Lmo or Spy) reporters (see Figure 1A schematic) designed to measure protein levels in *Listeria* contain a single RBS generating a fused Cas9-mCherry protein. Reporters for mRNA levels contain two ribosomal binding sites, one for Cas9 and a second for mCherry, generating two separate proteins. All reporters were conjugated into *Lmo10403s* devoid of endogenous *cas9* generating strains with the genotype *cas9*, *tRNAArg::pPL2oexL-pHyper-Cas9Reporter*. Cells were grown and data collected and processed as in “bacterial growth and fluorescence measurements.” Data are shown as the percentage of Cas9 translation and transcription levels (mCherry fluorescence averaged across 6 hr of logarithmic growth) relative to control strains (no prophage (–prophage) or empty vector, as indicated) of at least three biological replicates \pm SD (error bars).

RT-qPCR of *cas9* mRNA levels—WT or Cas9-overexpressing *Lmo10403s* (*cas9*, *tRNAArg::pPL2oexL-LmoCas9-6xHis-FLAG*) strains were grown to early (OD₆₀₀ 0.2–0.3) or mid-log (OD₆₀₀ 0.4–0.6) phase and 1.6 OD₆₀₀ units of cells were harvested as in “*Listeria* protein samples.” Cell pellets were resuspended in 100 μ L TE buffer supplemented with 0.2 U/ μ L SUPERase•In RNase Inhibitor (Thermo Fisher Scientific) and 5 mg/mL lysozyme, and incubated at 37°C for 10 min. Each sample was mixed with solutions pre-heated to 65°C for 15 min: 600 μ L hot 1.2X lysis buffer (60 mM NaOAc, 1.2% SDS, 12 mM EDTA) and 700 μ L hot acid-phenol:chloroform pH 4.5 (with IAA, 125:24:1) (Ambion). After incubating at 65°C for 30 min with shaking at 1500 rpm, followed by centrifugation at 12000 g for 15 min at 4°C, 500 μ L aqueous phase was recovered for each sample. RNA was extracted with neutral phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) three times, precipitated with ethanol, and resuspended in nuclease-free water. Residual DNA was removed using the TURBO DNA-free Kit (Invitrogen). RT-qPCR was conducted in technical triplicate using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs) according to the manufacturer’s instructions in 10 μ L reaction volumes and reactions were run on a CFX Real-Time PCR Detection System (BioRad). *cas9* mRNA and *16sRNA* were analyzed with the following primers: *cas9*-FWD: 5’-ATGCCGCGATAGATGGTTAC-3’ and *cas9*-REV: 5’-CGCCTTCGATGTTCTCCAATA-3’; *16s*-FWD: 5’-CCTGGTAGTCCACGCCGT-3’ and *16s*-REV: 5’-TGCGTTAGCTGCAGCACTAAG-3’.

SpyCas9 protein decay measurements in *Lmo*—Saturated overnight cultures of *Lmo10403s* strains devoid of endogenous *cas9* and expressing AcrIIA1 or AcrIIA4 from a tightly regulated rhamnose-inducible promoter (Fieseler et al., 2012) and SpyCas9-mCherry from the constitutively active pHyper promoter (*cas9*, *tRNAArg::pPL2oexL-pHyper-SpyCas9-mCherry-GyrA_terminator-pRha-AcrIIA*) were diluted 1:100 in fresh LB supplemented with 50 mM glycerol and tetracycline (2 µg /mL) and grown to mid-log (OD₆₀₀ ~0.5). Cultures were then diluted 1:2 in LB containing 50 mM glycerol and tetracycline (2 µg /mL) plus 200 mM rhamnose to induce Acr expression or 200 mM glycerol for uninduced controls (100 mM final concentration rhamnose or glycerol) in a 96-well microplate and treated with gentamicin (5 µg/mL) to inhibit translation or water as a control. Cells were grown and data collected and processed as in “bacterial growth and fluorescence measurements.” Data are shown as the mean percentage of SpyCas9-mCherry fluorescence relative to levels measured at “0 hr” (the beginning of translation inhibition or anti-CRISPR induction) of at least three biological replicates ± SD (error bars) as a function of time (min). Data were fitted by nonlinear regression to generate best-fit decay curves.

***Listeria* CRISPRi and self-targeting**—Single-copy integrating CRISPRi and self-targeting constructs (see Figure 2A and 2B schematics) were designed as follows: pPL2oexL–pHyper-sgRNA [pHELP-spacer] GyrATerminator–pRhamnose-Cas9 (*Lmo* WT or *Lmo* dead or Spy dead) LambdaTerminator–pHELP-mCherry-LuxTerminator and conjugated into *Lmo10403s* ϕ cure *cas9* containing pLEB579 plasmids expressing the indicated anti-CRISPRs. Overnight cultures were grown in LB supplemented with 50 mM glycerol (no induction/repression), 2 µg/mL tetracycline, and 7.5 µg/mL erythromycin. Cultures were then diluted 1:100 in LB containing 50 mM glycerol and the aforementioned antibiotics plus 200 mM rhamnose to induce Cas9 expression (and thus, CRISPRi or self-targeting) or 200 mM glycerol for uninduced controls (100 mM final concentration rhamnose or glycerol) in a 96-well microplate. Cells were grown and data collected and processed as in “bacterial growth and fluorescence measurements.” For self-targeting, data are displayed as the mean OD₆₀₀ of at least three biological replicates ± SD (error bars) as a function of time (hr). For CRISPRi, data are shown as the mean percentage mCherry expression (mCherry fluorescence averaged across 6 hr of logarithmic growth) relative to uninduced controls of at least three biological replicates ± SD (error bars).

Construction of isogenic ϕ A006 Acr phages—Isogenic ϕ A006 phages encoding distinct anti-CRISPRs from the native anti-CRISPR locus were engineered by rebooting genomic bacteriophage DNA in *L. monocytogenes* L-form cells (EGDe strain variant Rev2) as previously described (Kilcher et al., 2018). Denoted *acr* genes (*) contain the strong ribosomal binding site (RBS) naturally associated with the first gene in the natural ϕ A006 anti-CRISPR locus (*orfA*) whereas unmarked genes contain the weaker RBS associated with *acrIIA1*.

Cas9 and anti-CRISPR protein purifications—N-terminally 6xHis-tagged Acr proteins were expressed from the pET28 vector whereas WT SpyCas9 and mutants were expressed from 6xHis-MBP-Cas9 constructs (gifts from Jennifer Doudna, UC Berkeley) in *E. coli* Rosetta (DE3) pLysS cells. Recombinant protein expression was induced with 0.25

mM isopropyl β -D-1-thiogalactopyranoside (IPTG) at 18 °C overnight. Cells were harvested by centrifugation and lysed by sonication in buffer A (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.5 mM DTT, 20 mM imidazole, 5% glycerol) supplemented with 1 mM PMSF and 0.25 mg/mL lysozyme (Sigma). Cell debris was removed by centrifugation at 20000 g for 40 min at 4 °C and the lysate incubated with Ni-NTA Agarose Beads (Qiagen). After washing, bound proteins were eluted with Buffer A containing 300 mM imidazole and dialyzed overnight into storage buffer (20 mM HEPES-NaOH pH 7.4, 150mM KCl, 10% glycerol, 2mM DTT). GST-tagged AcrIIA1 and AcrIIA2b.3 were expressed from pGEX-6P-1 plasmids in *E. coli* BL21 (DE3) cells, lysed in buffer (20 mM HEPES-NaOH pH 7.4, 300 mM KCl and 5 mM DTT) supplemented with 1 mM PMSF and 0.25 mg/mL lysozyme, and clarified lysate was incubated with Glutathione Agarose Beads (Pierce). After washing, bound proteins were eluted using 100 mM Tris-HCl pH 8.5, 150 mM KCl, 15 mM reduced glutathione. The GST tag was cleaved with PreScission Protease (Millipore) and proteins were dialyzed overnight in 50 mM HEPES-NaOH pH 7.5, 150 mM KCl, 10% glycerol and 2 mM DTT to remove free glutathione. Cleaved GST was removed from dialyzed proteins with Glutathione Agarose Beads (Pierce).

***in vitro* binding of anti-CRISPRs to SpyCas9**—The binding affinities of Acr proteins to SpyCas9 were calculated using microscale thermophoresis (MST) on the Monolith NT.115 instrument (NanoTemper Technologies GmbH, Munich, Germany). For AcrIIA1/AcrIIA2b.3 with Cas9-gRNA complexes (WT, mutant, DNA-bound, or AcrIIA2b.3-bound) 6xHis-Cas9 proteins were incubated with two-fold molar excess gRNA (Integrated DNA Technologies) and labeled with RED-tris-NTA using the His-Tag labeling kit. To form the Cas9-gRNA-DNA or Cas9-gRNA-AcrIIA2b.3 complexes, two fold molar excess of a bubbled DNA substrate (whose target strand cannot be cleaved by the HNH domain due to mismatches in the seed) or AcrIIA2b.3 was incubated with Cas9-gRNA complex for 10 min at room temperature (RT). The substrate proteins AcrIIA1/AcrIIA2b.3 at 0.09 nM to 3 μ M concentrations were then incubated with 25 nM labeled Cas9-gRNA complexes at RT for 10 min in MST buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 15 mM MgCl₂, 0.05% Tween-20). For AcrIIA1/AcrIIA2b.3 with ApoCas9, the substrate protein ApoCas9 (QB3 Macrolab) at 0.61 nM to 10 μ M concentrations was incubated with 25 nM NT-647-NHS-labeled AcrIIA1/A2b.3 proteins. For AcrIIA1 mutants with WT Cas9-gRNA, the substrate protein Cas9-gRNA (QB3 Macrolab) at 15 pM to 0.5 μ M concentrations was incubated with 25 nM RED-tris-NTA-labeled 6xHis-AcrIIA1 mutant proteins. Samples were loaded into Monolith NT.115 Capillaries and measurements were performed at 25 °C using 40% LED power and medium microscale thermophoresis power. All experiments were repeated three times for each measurement. Data analysis was conducted using NanoTemper analysis software. For the Cas9-gRNA-DNA complex, the target dsDNA sequence for the top and bottom strands are as follows:

5'-
 CTCAGCCTGGAAGAGATCGTAACGCGAACTACGCGGGTTGGTATACCAACATCAT
 GACCT-3'

5'-

AGGTCATGATGTTGGTATACCATGGGGCGTAGTTCGCGTTACGATCTCTTCCAGGC
TGAG-3'

***in vitro* pull-downs of SpyCas9-Acr complexes**—5 µg apoCas9 proteins (WT, dead, D10A, or H840A) were incubated with two-fold molar excess gRNA at 37°C for 15 min. Cas9-gRNA complexes were then incubated with 10-fold molar excess GST-tagged AcrIIA1 or AcrIIA2b.3 proteins for 15 min at RT in binding buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 10% glycerol, 10 mM MgSO₄, 0.05% Tween 20 and 1 mM DTT). Samples were then incubated with 20 µL Glutathione sepharose beads (GE) for 15 min at 4°C and washed five times with binding buffer. Beads were boiled in 1X Laemmli Sample Buffer and proteins were analyzed by SDS-PAGE and Bio-Safe Coomassie staining (Biorad).

Cas9 DNA cleavage with purified proteins—To generate gRNAs, crRNA and tracrRNA were annealed with Nuclease-free Duplex Buffer (Integrated DNA Technologies) according to the manufacturer's instructions. *In vitro* Cas9 DNA cleavage reactions were assembled in 1X MST Buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 20 mM MgCl₂, 5 mM DTT, 5% glycerol, 0.05% (v/v) Tween-20) with 50 nM SpyCas9 and 625 nM AcrIIA, incubated for 5 min on ice, supplemented with 50 nM gRNA, and incubated for an additional 5 min at room temperature. Reactions were initiated by adding 2 nM target DNA substrate and at 1, 2, 5 and 10 min time points reaction aliquots were mixed with warm Quenching Buffer (50mM EDTA, 0.02% SDS) and boiled at 95°C for 10 min. DNA cleavage products were analyzed by agarose (1%) gel electrophoresis and staining with SYBR Safe (Thermo Fisher Scientific).

SpyCas9-AcrIIA1 limited proteolysis—20 µg purified SpyCas9 (QB3 Macrolab) in Apo form or in complex with gRNA (1.1-fold molar excess) was incubated with 1.5-fold and 4-fold molar excess AcrIIA1 and AcrIIA2b.3, respectively, in protease buffer (10 mM Tris-HCl pH 7.5, 300 mM NaCl) at 25°C for 15 min. Alternatively, ApoSpyCas9 was incubated first with AcrIIA protein followed by gRNA addition. Proteolysis reactions were performed with 20 ng α-chymotrypsin (sequencing grade, Promega) at 25°C and at 0, 10, 30, or 60 min time points, reactions were quenched with 2X SDS Laemmli Buffer and boiled for 10 min at 95°C. Samples were analyzed by SDS-PAGE and staining with Bio-Safe Coomassie (Bio-Rad).

Phage plaque forming unit quantification—*Listeria* phage infections were conducted using the soft agar overlay method: 10 µL phage dilution was mixed with 150 µL stationary *Listeria* culture in 3 mL molten LC top agar supplemented with 300 µg/mL Tetrazolium Violet (TCI Chemicals) to generate contrast for plaque visualization (Hurst et al., 1994) and poured onto a BHI-agar plate. After 24 hr incubation at 30°C, phage plaque-forming units (PFU) were quantified.

Efficiency of plaquing of *Listeria* phages—Efficiency of plaquing (EOP) calculations are a ratio of the number of plaque forming units (PFUs) that formed on a *Lmo10403s*ϕcure targeting strain (endogenous *cas9* with overexpression of the native CRISPR array spacer #1 that targets ϕA006) divided by the number of PFUs that formed on a non-targeting strain

(*cas9*). Each PFU measurement was conducted in biological triplicate and all EOP data is displayed as the mean EOP \pm SD (error bars).

Construction of self-targeting *Lmo* lysogens—*Lmo10403s cas9:: ϕ A006* isogenic self-targeting lysogens encoding no anti-CRISPR or AcrIIA1, AcrIIA4, AcrIIA12 (alone or in combination as indicated) were isolated as in “construction of *Lmo10403s* lysogens.” To prevent self-targeting during strain construction, pPL2oexL constructs encoding a tightly regulated rhamnose-inducible LmoCas9 (WT or dead as a control) were conjugated into each lysogen. To assess the stability of each lysogen, cells were cultured, Cas9 induced, and data displayed as described for the self-targeting strain in “*Listeria* CRISPRi and self-targeting,” except erythromycin was omitted from LB media. Each lysogen stability measurement was performed in biological triplicate.

***P. aeruginosa* anti-SpyCas9 screening platform**—The previously described *P. aeruginosa* anti-SpyCas9 screening platform (Jiang et al., 2019) and bacteriophage plaque assays (Borges et al., 2018; Jiang et al., 2019) were utilized to assay the anti-CRISPR activity of AcrIIA1 homologs and mutants. AcrIIA1 homolog genes were synthesized (Twist Bioscience) and cloned into the pMMB67HE- P_{Lac} vector. Protein accession numbers are listed in Table S1. Site directed mutagenesis by Gibson Assembly was used to introduce point mutations into pMMB67HE- P_{Lac} -GST-AcrIIA1. The P_{BAD} promoter driving chromosomally integrated SpyCas9–3xMyc and pHERD30T-sgRNA was induced with 0.1% arabinose and the P_{Lac} promoter driving pMMB67HE-AcrIIA with 1 mM IPTG. Expression of AcrIIA1 mutants was confirmed by harvesting 1 OD₆₀₀ unit of cells and resuspending in 200 μ L 1X Laemmli Sample Buffer (Bio-Rad) followed by SDS-PAGE and immunoblotting as described above. The fold reductions in phage titer displayed were qualitatively derived by examining at least three replicates of each experiment. Plate images were acquired as in “*Listeria* phage titering” and a representative picture is shown.

***P. aeruginosa* self-targeting and CRISPRi**—Strains were generated as previously described by Borges et al., 2018 under “construction of PAO1::SpyCas9 expression strain,” except the sgRNA was designed to target the PAO1 chromosomal *phzM* gene promoter and was integrated into the bacterial genome using the mini-CTX2 vector (Hoang et al., 2000). Cultures were grown overnight in LB supplemented with 50 μ g/mL gentamicin and 0.1% arabinose to pre-induce anti-CRISPR expression and the next day diluted 1:100 with fresh LB containing 50 μ g/mL gentamicin, 0.1% arabinose, and IPTG (0, 0.01, 0.1 or 1mM to titrate WT or dead SpyCas9-sgRNA expression) in a 96-well microplate (150 μ L/well) for self-targeting analysis or glass tubes (3 mL) for CRISPRi. Self-targeting experiments were conducted in biological triplicate with cells grown and data collected and processed as in “bacterial growth and fluorescence measurements.” For CRISPRi, cells were grown for 8–10 hr with continuous shaking after which CRISPRi was qualitatively assessed by inspecting the culture pigment. Repression of the *phzM* gene by dCas9 generates a yellow culture whereas inhibition of dCas9 (e.g. by an Acr) allows *phzM* expression and pyocyanin production that generates a green culture. Representative pictures of at least three biological replicates are shown.

SpyCas9–3xMyc and GST-AcrIIA co-IPs—Saturated overnight cultures of *P. aeruginosa* strains were diluted 1:100 in 50 mL of LB supplemented with required antibiotics, grown to OD₆₀₀ 0.3–0.4, and induced with 0.3% arabinose (SpyCas9-gRNA) and 1mM IPTG (anti-CRISPR). Cells were harvested at OD₆₀₀ 1.8–2.0 by centrifugation at 6000 g for 10 min at 4°C, flash frozen on dry ice, resuspended in 1 mL lysis buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 20 mM MgCl₂, 0.5% NP-40, 5% (v/v) glycerol, 5 mM DTT, 1 mM PMSF), lysed by sonication (20 sec pulse × 4 cycles with cooling between cycles), and lysate was clarified by centrifugation at 14 000g for 10 min at 4°C. For input samples, 10 µL lysate was mixed with one-third volume 4X Laemmli Sample Buffer. Remaining lysate (~1 mL) was mixed with pre-washed Myc-Tag Magnetic Bead Conjugate #5698 (Cell Signaling Technology) or Glutathione Magnetic Agarose Beads #78601 (Thermo Fisher Scientific) using a lysate to bead slurry volume ratio of 20:1 for Myc or 40:1 for GST. After overnight incubation at 4°C with end-over-end rotation, beads were washed five times with 1 mL cold wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 mM MgCl₂, 5mM DTT) containing decreasing concentrations of NP-40 (0.5%, 0.05%, 0.01%, 0.005%, 0) and glycerol (5%, 0.5%, 0.05%, 0.005%, 0) on a magnetic stand. Bead-bound proteins were resuspended in 100 µL wash buffer without detergent and glycerol. 10 µL bead-bound protein slurry was mixed with one-third volume 4X Laemmli Sample Buffer, boiled for 5 min at 95°C, and samples were analyzed by SDS-PAGE using 4–20% Mini-PROTEAN TGX gels (Bio-Rad) and staining with Bio-Safe Coomassie (Bio-Rad) or immunoblotting.

Immunoprecipitated SpyCas9 DNA cleavage assay—SpyCas9–3xMyc DNA cleavage reactions were assembled with bead-bound protein slurry and 1.5 nM DNA substrate, incubated at 25°C with gentle shaking at 1000 rpm, and at 1, 5, 10, and 30 min time points reaction aliquots were mixed with warm Quenching Buffer (50 mM EDTA, 0.02% SDS) and boiled at 95°C for 10 min. DNA cleavage products were analyzed by agarose (1%) gel electrophoresis and staining with SYBR Safe (Thermo Fisher Scientific).

Inhibition of *LivCas9* by anti-CRISPR proteins—Plaquing assays were conducted as previously described by Hupfeld et al., 2018. A *Listeria monocytogenes* Mack strain containing chromosomally-integrated pHelp-LivCas9/tracrRNA was transformed with pLEB579-derived plasmids constructed to express two components: an Acr protein from the pSpac promoter (or no Acr) and a crRNA that targets phage ΦP35 (or a scrambled non-targeting control). A *Listeria ivanovii* WSLC 30167 strain containing an endogenous Type II-A LivCas9 system was transformed with a pKSV7-derived plasmid expressing AcrIIA1 from the ΦA006 anti-CRISPR promoter (or empty vector) and a pLRSR-crRNA plasmid that targets phage ΦA511 (or a non-targeting control). A mixture of 200 µL stationary host culture and 4 mL LC top agar was poured onto an agar plate (LC for ΦP35; 1/2 BHI for ΦA511). Ten-fold serial dilutions of phage were spotted on top, plates were incubated at 20°C for ΦP35 and 30°C for ΦA511 for one day, and plate images were subsequently acquired.

***E. coli* phage Mu plaquing assays**—Plasmids expressing Type II-A, II-B, and II-C Cas9-sgRNA combinations were previously described (Garcia et al., 2019). Cas9 plasmids containing a spacer targeting phage Mu and a pCDF-1b plasmid expressing the indicated

anti-CRISPR proteins were co-transformed into *E. coli* BB101. After 2 hr of growth in LB at 37°C with continuous shaking, cells were treated with 0.01 mM IPTG to induce anti-CRISPR expression, and incubated for an additional 3 hr. A mixture of cells and LB top agar (0.7% agar) was poured onto an LB plate supplemented with 200 ng/mL aTc, 0.2% arabinose, and 10 mM MgSO₄. Ten-fold serial dilutions of phage Mu were spotted on top and plates were incubated overnight. Anti-CRISPR expression after IPTG induction was analyzed by SDS-PAGE on a 15% Tris-Tricine gel followed by Coomassie Blue staining as previously described (Lee et al., 2018).

Generation of human cell expression plasmids—Descriptions of plasmids used for expression of sgRNAs (including sgRNA/crRNA target sequences), nucleases, and Acr proteins in human cells are available in Table S3. U6 promoter sgRNA and crRNA expression plasmids were generated by annealing and ligating oligonucleotide duplexes into BsmBI-digested BPK1520, BPK2660, KAC14, KAC27, KAC482, KAC32 and BPK4449 for SpyCas9, SauCas9, St1Cas9, St3Cas9, CjeCas9, and NmeCas9, respectively. New human cell expression plasmids for CjeCas9, St3Cas9, and NmeCas9 were generated by sub-cloning the nuclease open-reading frames of Addgene plasmids # 89752, 68337, and 119923, respectively (gifts from Seokjoong Kim, Feng Zhang and Erik Sontheimer) into the AgeI and NotI sites of pCAG-CFP (Addgene plasmid 11179; a gift from C. Cepko). Human codon optimized Acr constructs containing a C-terminal SV40 nuclear localization signal were generated by isothermal assembly of synthetic gene fragments (Twist Biosciences) into the NotI and AgeI sites of Addgene plasmid ID 43861. New human expression plasmids described in this study have been deposited with Addgene (see Table S3).

Transfection of human cells—Approximately 20 hours prior to transfection, HEK 293T cells were seeded at 2×10^4 cells/well in 96-well plates. Cells were transfected using 70 ng of nuclease, 30 ng sgRNA/crRNA, and 110 ng of acr expression plasmids with 1.25 μ L of *TransIT-X2* (Mirus Bio) in 20 μ L Opti-MEM. For control conditions containing no acr plasmid, 110 ng of a pCMV-EGFP plasmid was utilized as filler DNA; for non-targeting sgRNA/crRNA conditions, 30 ng of an empty U6 promoter plasmid was used as filler DNA. For titration experiments cells were transfected using 70 ng of nuclease, 30 ng sgRNA/crRNA, varying amounts of acr expression and DNA stuffer plasmids totaling 197 ng (6 ng acr with 191 ng stuffer; 22 ng acr with 175 stuffer; 62 ng acr with 135 stuffer; 197 ng acr with no stuffer), and 1.77 μ L of *TransIT-X2* (Mirus Bio) in 20 μ L Opti-MEM. DNA stuffer plasmids were an orthogonal and incompatible pCAG-nuclease expression plasmid. Genomic DNA was harvested from cells 72 hours post-transfection by suspending cells in 100 μ L of lysis buffer (20 mM Hepes pH 7.5, 100 mM KCl, 5 mM MgCl₂, 5% glycerol, 25 mM DTT, 0.1% Triton X-100, and 30 ng/uL Proteinase K (NEB)), followed by incubation at 65°C for 6 minutes and 98°C for 2 minutes. All experiments were performed with at least 3 independent biological replicates.

Cas and Acr protein activities in human cells—Genome editing efficiencies were determined by next-generation sequencing using a 2-step PCR-based Illumina library construction method (for primers see Table S4). Briefly, genomic regions were initially amplified using Q5 High-Fidelity DNA Polymerase (NEB), ~100 ng of genomic DNA

lysate, and gene-specific round 1 primers. PCR products were purified using paramagnetic beads as previously described (Kleinstiver et al., 2019) and diluted 1:100 prior to the 2nd round of PCR to add Illumina barcodes and adapter sequences using Q5 polymerase. PCR amplicons were bead purified, quantified and normalized (Qiagen QIAxcel), and pooled. Final libraries were quantified using an Illumina Library qPCR Quantification Kit (KAPA Biosystems) and sequenced on a MiSeq sequencer using a 300-cycle v2 kit (Illumina). Genome editing activities were determined from the sequencing data using CRISPResso2 (Clement et al., 2019) with commands --min_reads_to_use_region 100. -w 10, and for certain sequencing data sets --ignore_substitutions. The known control inhibitors that were used included: AcrIIA4 SpyCas9 inhibitor (Dong et al., 2017), AcrIIA5 broad-spectrum Cas9 inhibitor (Garcia et al., 2019), AcrVA1 Cas12 inhibitor as a negative control for Cas9 orthologues (Marino et al., 2018).

QUANTIFICATION AND STATISTICAL ANALYSIS

All numerical data, with the exception of the microscale thermophoresis (MST) data, were analyzed and plotted using GraphPad Prism 6.0 software. The MST data were analyzed using the NanoTemper analysis software (NanoTemper Technologies GmbH) and plotted using GraphPad Prism 6.0 software. Statistical parameters are reported in the Figure Legends.

Data and Code Availability—The AcrIIA1 homolog protein accession numbers and associated promoter sequences are disclosed in Table S1.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We would like to thank Daniel A. Portnoy (UC Berkeley) for providing the pLMB3C-pRhamnose plasmid, Jennifer A. Doudna for Cas9 expression plasmids (UC Berkeley), and Jonathan Asfaha (David Morgan Lab, UCSF) and Ujjwal Rathore (Alex Marson Lab, UCSF) for experimental advice and reagents. The J.B.-D lab was supported by the UCSF Program for Breakthrough Biomedical Research funded in part by the Sandler Foundation, the Searle Fellowship, the Vallee Foundation, the Innovative Genomics Institute, an NIH Director's Early Independence Award DP5-OD021344, and R01GM127489; S.Ki. lab was supported by an Ambizione Fellowship (Swiss National Science Foundation, PZ00P3_174108); the B.P.K. lab by NIH R00-CA218870 and P01-HL142494, an A.S.G.C.T. Career Development Award, and the Margaret Q. Landenberger Research Foundation; and the A.R.D. lab by a CIHR Foundation grant FDN-15427.

REFERENCES

- Argov T, Azulay G, Pasechnek A, Stadnyuk O, Ran-Sapir S, Borovok I, Sigal N, and Herskovits AA (2017). Temperate bacteriophages as regulators of host behavior. *Curr. Opin. Microbiol* 38, 81–87. [PubMed: 28544996]
- Beasley SS, Takala TM, Reunanen J, Apajalahti J, and Saris PEJ (2004). Characterization and Electrotransformation of *Lactobacillus Crispatus* Isolated from Chicken Crop and Intestine. *Poult. Sci* 83, 45–48. [PubMed: 14761083]
- Bondy-Denomy J, Garcia B, Strum S, Du M, Rollins MF, Hidalgo-Reyes Y, Wiedenheft B, Maxwell KL, and Davidson AR (2015). Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins. *Nature* 526, 136–139. [PubMed: 26416740]

- Bondy-Denomy J, Qian J, Westra ER, Buckling A, Guttman DS, Davidson AR, and Maxwell KL (2016). Prophages mediate defense against phage infection through diverse mechanisms. *ISME J.* 10, 2854–2866. [PubMed: 27258950]
- Borges AL, Davidson AR, and Bondy-Denomy J (2017). The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs. *Annu. Rev. Virol* 4, null.
- Borges AL, Zhang JY, Rollins M, Osuna BA, Wiedenheft B, and Bondy-Denomy J (2018). Bacteriophage cooperation suppresses CRISPR-Cas3 and Cas9 immunity. *BioRxiv* 279141.
- Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, Makarova KS, Koonin EV, and van der Oost J (2008). Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes. *Science* 321, 960–964. [PubMed: 18703739]
- Choi K-H, Kumar A, and Schweizer HP (2006). A 10-min method for preparation of highly electrocompetent *Pseudomonas aeruginosa* cells: Application for DNA fragment transfer between chromosomes and plasmid transformation. *J. Microbiol. Methods* 64, 391–397. [PubMed: 15987659]
- Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, Cole MA, Liu DR, Joung JK, Bauer DE, et al. (2019). CRISPResso2 provides accurate and rapid genome editing sequence analysis. *Nat. Biotechnol* 37, 224–226. [PubMed: 30809026]
- Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirezada ZA, Eckert MR, Vogel J, and Charpentier E (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* 471, 602–607. [PubMed: 21455174]
- Dong D, Guo M, Wang S, Zhu Y, Wang S, Xiong Z, Yang J, Xu Z, and Huang Z (2017). Structural basis of CRISPR–SpyCas9 inhibition by an anti-CRISPR protein. *Nature* 546, 436–439. [PubMed: 28448066]
- Estela LA, Sofos JN, and Flores BB (1992). Bacteriophage Typing of *Listeria monocytogenes* Cultures Isolated From Seafoods. *J. Food Prot* 55, 13–17. [PubMed: 31071804]
- Feiner R, Argov T, Rabinovich L, Sigal N, Borovok I, and Herskovits AA (2015). A new perspective on lysogeny: prophages as active regulatory switches of bacteria. *Nat. Rev. Microbiol* 13, 641–650. [PubMed: 26373372]
- Fieseler L, Schmitter S, Teiserskas J, and Loessner MJ (2012). Rhamnose-Inducible Gene Expression in *Listeria monocytogenes*. *PLoS ONE* 7, e43444. [PubMed: 22927968]
- Fuchsbauer O, Swuec P, Zimmerger C, Amigues B, Levesque S, Agudelo D, Durringer A, Chaves-Sanjuan A, Spinelli S, Rousseau GM, et al. (2019). Cas9 Allosteric Inhibition by the Anti-CRISPR Protein AcrIIA6. *Mol. Cell*
- Garcia B, Lee J, Edraki A, Hidalgo-Reyes Y, Erwood S, Mir A, Trost CN, Seroussi U, Stanley SY, Cohn RD, et al. (2019). Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing. *Cell Rep.* 29, 1739–1746.e5. [PubMed: 31722192]
- Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, and Moineau S (2010). The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature* 468, 67–71. [PubMed: 21048762]
- Harrington LB, Doxzen KW, Ma E, Liu J-J, Knott GJ, Edraki A, Garcia B, Amrani N, Chen JS, Cofsky JC, et al. (2017). A Broad-Spectrum Inhibitor of CRISPR-Cas9. *Cell* 170, 1224–1233.e15. [PubMed: 28844692]
- Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, and Doudna JA (2010). Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease. *Science* 329, 1355–1358. [PubMed: 20829488]
- Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, and Marraffini LA (2015). Cas9 specifies functional viral targets during CRISPR–Cas adaptation. *Nature* 519, 199–202. [PubMed: 25707807]
- Hoang TT, Kutchma AJ, Becher A, and Schweizer HP (2000). Integration-Proficient Plasmids for *Pseudomonas aeruginosa*: Site-Specific Integration and Use for Engineering of Reporter and Expression Strains. *Plasmid* 43, 59–72. [PubMed: 10610820]
- Hupfeld M, Trasanidou D, Ramazzini L, Klumpp J, Loessner MJ, and Kilcher S (2018). A functional type II-A CRISPR–Cas system from *Listeria* enables efficient genome editing of large non-integrating bacteriophage. *Nucleic Acids Res.* 46, 6920–6933. [PubMed: 30053228]

- Hurst CJ, Blannon JC, Hardaway RL, and Jackson WC (1994). Differential Effect of Tetrazolium Dyes upon Bacteriophage Plaque Assay Titers. *Appl Env. Microbiol* 60, 3462–3465. [PubMed: 16349397]
- Hwang S, and Maxwell KL (2019). Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems. *CRISPR J.* 2, 23–30. [PubMed: 31021234]
- Hynes AP, Rousseau GM, Lemay M-L, Horvath P, Romero DA, Fremaux C, and Moineau S (2017). An anti-CRISPR from a virulent streptococcal phage inhibits *Streptococcus pyogenes* Cas9. *Nat. Microbiol* 2, 1374. [PubMed: 28785032]
- Hynes AP, Rousseau GM, Agudelo D, Goulet A, Amigues B, Loehr J, Romero DA, Fremaux C, Horvath P, Doyon Y, et al. (2018). Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a range of Cas9 proteins. *Nat. Commun* 9, 2919. [PubMed: 30046034]
- Jiang F, Liu J-J, Osuna BA, Xu M, Berry JD, Rauch BJ, Nogales E, Bondy-Denomy J, and Doudna JA (2019). Temperature-Responsive Competitive Inhibition of CRISPR-Cas9. *Mol. Cell* 73, 601–610.e5. [PubMed: 30595438]
- Ka D, An SY, Suh J-Y, and Bae E (2018). Crystal structure of an anti-CRISPR protein, AcrIIA1. *Nucleic Acids Res.* 46, 485–492. [PubMed: 29182776]
- Kilcher S, Studer P, Muessner C, Klumpp J, and Loessner MJ (2018). Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. *Proc. Natl. Acad. Sci* 115, 567–572. [PubMed: 29298913]
- Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, et al. (2019). Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. *Nat. Biotechnol* 37, 276–282. [PubMed: 30742127]
- Koonin EV, Makarova KS, and Zhang F (2017). Diversity, classification and evolution of CRISPR-Cas systems. *Curr. Opin. Microbiol* 37, 67–78. [PubMed: 28605718]
- Lauer P, Chow MYN, Loessner MJ, Portnoy DA, and Calendar R (2002). Construction, Characterization, and Use of Two *Listeria monocytogenes* Site-Specific Phage Integration Vectors. *J BACTERIOL* 184, 11.
- Lee J, Mir A, Edraki A, Garcia B, Amrani N, Lou HE, Gainetdinov I, Pawluk A, Ibraheim R, Gao XD, et al. (2018). Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins. *MBio* 9, e02321–18. /mbio/9/6/mbio.02321–18.atom. [PubMed: 30514786]
- Liu L, Yin M, Wang M, and Wang Y (2019). Phage AcrIIA2 DNA Mimicry: Structural Basis of the CRISPR and Anti-CRISPR Arms Race. *Mol. Cell* 73, 611–620.e3. [PubMed: 30606466]
- Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJJ, Charpentier E, Haft DH, et al. (2015). An updated evolutionary classification of CRISPR–Cas systems. *Nat. Rev. Microbiol* 13, 722–736. [PubMed: 26411297]
- Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, Walton RT, Berry JD, Joung JK, Kleinstiver BP, et al. (2018). Discovery of widespread type I and type V CRISPR-Cas inhibitors. *Science* 362, 240–242. [PubMed: 30190308]
- Mathony J, Hartevelde Z, Schmelas C, Upmeier zu Belzen J, Aschenbrenner S, Hoffmann MD, Stengl C, Scheck A, Rosset S, Grimm D, et al. (2019). Computational design of anti-CRISPR proteins with improved inhibition potency and expanded specificity. *BioRxiv* 685032.
- Mojica FJM, Díez-Villaseñor C, García-Martínez J, and Soria E (2005). Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements. *J. Mol. Evol* 60, 174–182. [PubMed: 15791728]
- Nakamura M, Srinivasan P, Chavez M, Carter MA, Dominguez AA, La Russa M, Lau MB, Abbott TR, Xu X, Zhao D, et al. (2019). Anti-CRISPR-mediated control of gene editing and synthetic circuits in eukaryotic cells. *Nat. Commun* 10, 194. [PubMed: 30643127]
- Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, and Doudna JA (2014). Cas1–Cas2 complex formation mediates spacer acquisition during CRISPR–Cas adaptive immunity. *Nat. Struct. Mol. Biol* 21, 528–534. [PubMed: 24793649]
- Osuna BA, Karambelkar S, Mahendra C, Kilcher S, and Bondy-Denomy J (2020b). Critical anti-CRISPR locus repression by a bi-functional Cas9 inhibitor. co-submitted companion manuscript

- Park SF, and Stewart GSAB (1990). High-efficiency transformation of *Listeria monocytogenes* by electroporation of penicillin-treated cells. *Gene* 94, 129–132. [PubMed: 2121618]
- Rabinovich L, Sigal N, Borovok I, Nir-Paz R, and Herskovits AA (2012). Prophage Excision Activates *Listeria* Competence Genes that Promote Phagosomal Escape and Virulence. *Cell* 150, 792–802. [PubMed: 22901809]
- Rauch BJ, Silvis MR, Hultquist JF, Waters CS, McGregor MJ, Krogan NJ, and Bondy-Denomy J (2017). Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* 168, 150–158.e10. [PubMed: 28041849]
- Simon R, Priefer U, and Pühler A (1983). A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria. *Bio/Technology* 1, 784–791.
- Thavalingam A, Cheng Z, Garcia B, Huang X, Shah M, Sun W, Wang M, Harrington L, Hwang S, Hidalgo-Reyes Y, et al. (2019). Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2. *Nat. Commun* 10, 2806. [PubMed: 31243272]
- Trasanidou D, Gerós AS, Mohanraju P, Nieuwenweg AC, Nobrega FL, and Staals RHJ (2019). Keeping crspr in check: diverse mechanisms of phage-encoded anti-crisprs. *FEMS Microbiol. Lett* 366, fnz098. [PubMed: 31077304]
- Yosef I, Goren MG, and Qimron U (2012). Proteins and DNA elements essential for the CRISPR adaptation process in *Escherichia coli*. *Nucleic Acids Res.* 40, 5569–5576. [PubMed: 22402487]
- Zhu Y, Gao A, Zhan Q, Wang Y, Feng H, Liu S, Gao G, Serganov A, and Gao P (2019). Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type IIC Anti-CRISPR Proteins. *Mol. Cell* 74, 296–309.e7. [PubMed: 30850331]

Highlights

- *Listeria* phages use independent Cas9 inhibitors to support lytic and lysogenic stages
- AcrIIA1 induces degradation of Cas9 during lysogeny, but is ineffective in lytic growth
- AcrIIA1 binds directly to Apo or sgRNA-loaded Cas9 via the HNH domain
- AcrIIA1 has a broad spectrum of inactivation, inhibiting both *Listeria* Cas9 orthologues




Figure 1. AcrIIA1 Induces Cas9 Degradation in *Listeria*

(A-B) Immunoblots detecting FLAG-tagged LmoCas9 protein and a non-specific (ns) protein loading control in *Listeria monocytogenes* strain 10403s (*Lmo10403s*) lysogenized with the indicated wild-type prophages (A, top) or *Lmo10403s* containing Acr-expressing plasmids (B, top). Dashed lines indicate where intervening lanes were removed for clarity (B, top). Representative blots of at least three biological replicates are shown (A and B). Schematics of translational and transcriptional reporters used to measure Lmo or Spy Cas9 protein and mRNA levels in *Lmo10403s* (A, middle). Cas9 translational (black bars) and transcriptional (gray shaded bars) reporter measurements reflect the mean percentage mCherry relative fluorescence units (RFU/OD₆₀₀) in the indicated lysogens (A, bottom) or strains with Acr-expressing plasmids (B, bottom) relative to the control strain lacking a prophage (–prophage) (A, bottom) or containing an empty vector (B, bottom). Error bars represent the mean \pm SD of at least three biological replicates. (C) SpyCas9-mCherry protein levels post Acr induction or translation inhibition: *Lmo10403s* expressing SpyCas9-mCherry from the constitutively active pHyper promoter and AcrIIA1 or AcrIIA4 from an inducible promoter were grown to mid-log phase and treated with 100 mM rhamnose to induce Acr expression (dashed lines) or 100 mM glycerol as a neutral carbon source control (solid lines) and 5 μ g/mL gentamicin (Gent) to inhibit translation (+) or water (–) as a control. SpyCas9-mCherry protein measurements reflect the mean percentage fluorescence (RFU/OD₆₀₀) relative to the SpyCas9-mCherry levels at the time translation inhibition was initiated (0 min). Error bars (vertical lines) represent the mean \pm SD of at least three biological replicates. Data were fitted by nonlinear regression to generate best-fit decay curves. See Figure S1C for additional controls and S1B for data showing tight repression of the pRha promoter under non-inducing conditions. Note: *Lmo* doubling time is significantly slower in LB media containing glycerol and/or rhamnose carbon sources (Fieseler et al., 2012).




Figure 2. AcrIIA1 Selectively Binds Catalytically Active Cas9 to Trigger its Degradation (A-B) Acr-mediated inhibition of CRISPRi (A) or self-targeting (B). *Lmo10403s* contains chromosomally-integrated constructs expressing dead (A) or catalytically active (B) LmoCas9 from the inducible pRha-promoter and sgRNA that targets the pHelp-promoter driving mCherry expression. For CRISPRi, mCherry expression measurements reflect the mean percentage fluorescence (RFU/OD₆₀₀) in deadCas9-induced cells relative to uninduced controls (-dCas9) of three biological replicates ± SD (error bars) (A). For self-targeting, bacterial growth was monitored after LmoCas9 induction (orange lines) or no induction (blue lines) and data are displayed as the mean OD₆₀₀ of three biological replicates ± SD (error bars) (B). See Figure S2A for CRISPRi data with *Lmo10403s* expressing deadSpyCas9. (C) Translational (black bars) and transcriptional (gray shaded bars) reporter levels of catalytically active (left) and dead LmoCas9 (right) in *Lmo10403s* lysogenized with engineered isogenic Φ A006 prophages. Cas9 reporter measurements reflect the mean percentage mCherry relative fluorescence units (RFU/OD₆₀₀) in the indicated lysogens relative to the control strain lacking a prophage (-prophage). Error bars represent the mean ± SD of at least three biological replicates. Asterisk (*) denotes genes containing the native orfA RBS (strong) in Φ A006 and unmarked genes contain their native RBS. See Figure S2B for equivalent data with *Lmo10403s* expressing SpyCas9. (D) Quantification of the binding affinities (K_D; boxed inset) of Acr proteins for WT, catalytically dead (dCas9), or nickase (D10A or H840A) SpyCas9-gRNA complexes using microscale thermophoresis. Data shown are representative of three independent experiments. See Figure S2D for additional controls with AcrIIA2b.3 (IIA2, dashed line). (E) Time course of SpyCas9 DNA cleavage reactions in the presence of Acr proteins that were recombinantly purified from *E. coli*. Dashed lines indicate where intervening lanes were removed for

clarity. Solid lines indicate a separate image. Data shown are representative of three independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. AcrIIA1 Inhibits Cas9 to Protect Prophages During Lysogeny

(A) Left: Representative image of plaquing assays where isogenic Φ A006 phages are titrated in ten-fold serial dilutions (black spots) on a lawn of *Lmo10403s* (gray background). Dashed lines indicate where intervening rows were removed for clarity. Right: Efficiency of plaquing (EOP) of isogenic Φ A006 phages expressing the indicated Acrs on *Lmo10403s*. Plaque forming units (PFUs) were quantified on *Lmo10403s* overexpressing the first spacer in the native CRISPR array that targets Φ A006 (*cas9;pHyper-spacer#1*) and normalized to the number of PFUs measured on a non-targeting *Lmo10403s*-derived strain (*cas9*). Data are displayed as the mean EOP of at least three biological replicates \pm SD (error bars). See Figure S3A for EOP measurements of additional Φ A006 phages. (B) Bacterial growth curves of self-targeting *Lmo10403s:: Φ A006* isogenic lysogens expressing the indicated Acrs and rhamnose-inducible WT or dead *LmoCas9*. WT *LmoCas9* (blue lines) is lethal in an Acr-deficient (*acr*) strain because the *Lmo10403s* CRISPR array contains a spacer targeting the Φ A006 prophage integrated in the bacterial genome. Data are displayed as the mean OD₆₀₀ of at least three biological replicates \pm SD (error bars) as a function of time (min). Asterisk (*) indicates the native *orfA* RBS (strong) in Φ A006 was used for Acr expression.




Figure 4: AcrIIA1 Uses its C-terminal Domain to Lock Cas9 in an Inhibited State

(A) Left: Alignment of AcrIIA1 homolog protein sequences denoting key residues. Right: Phylogenetic tree of the protein sequences of AcrIIA1 homologs. See companion manuscript for a complete alignment of the AcrIIA1 homolog protein sequences (Osuna et al., 2020b).

(B-C) Fold reduction in phage titer in response to SpyCas9 targeting of a *P. aeruginosa* DMS3m-like phage in the presence of AcrIIA1 homologs (B) or mutants (C). The percent protein sequence identities of each homolog to the full-length (FL) or domains (NTD or CTD) of AcrIIA1 ϕ A006 are listed in (B). The displayed fold reductions in phage titer were qualitatively determined by examining three biological replicates of each phage-plaquing experiment. See Figure S4B for representative pictures of the corresponding phage-plaquing experiments.

(D) Immunoblots detecting GST-tagged anti-CRISPR proteins that co-immunoprecipitated with Myc-tagged SpyCas9 in a *P. aeruginosa* strain heterologously expressing Type II-A SpyCas9-gRNA and the indicated Acrs. For input samples, one-hundredth lysate volume was analyzed to verify tagged protein expression and RNA-polymerase was used as a loading control. Representative blots of three biological replicates are shown. See Figure S4E for the reciprocal GST-Acr pulldown.

(E) Time course of SpyCas9 DNA cleavage reactions conducted with SpyCas9-gRNA-Acr (or no Acr, -) complexes immunoprecipitated from *P. aeruginosa*. Dashed lines indicate where intervening lanes were removed for clarity. Data shown are representative of three independent experiments. See Figure S4F for reactions with AcrIIA1 mutants.




Figure 5. AcrIIA1 is a Broad-Spectrum Cas9 Inhibitor

(A) Phylogenetic tree of the protein sequences of Cas9 orthologues. The percent query coverage and percent protein sequence identities relative to *LmoCas9* are listed in parentheses. Cas9 orthologue names: *Francisella novicida* (*Fno*), *Listeria monocytogenes* (*Lmo*), *Streptococcus pyogenes* (*Spy*), *Staphylococcus aureus* (*Sau*), *Listeria ivanovii* (*Liv*), *Neisseria meningitidis* (*Nme*), *Haemophilus parainfluenzae* (*Hpa*), *Brackiella oedipodis* (*Boe*), *Geobacillus stearothermophilus* (*Geo*), *Campylobacter jejuni* (*Cje*), *Corynebacterium diphtheriae* (*Cdi*). (B) Plaque assays where the *Listeria* phage Φ P35 is titrated in ten-fold serial dilutions (black spots) on lawns of *L. monocytogenes* Mack (gray background) strains that express chromosomally-integrated LivCas9/tracrRNA and contain pLEB plasmids expressing two components: an Acr or no Acr (–) and a crRNA that targets phage DNA or a scrambled crRNA (non-targeting control). (C) Plaque assays where the *E. coli* phage Mu is titrated in ten-fold serial dilutions (black spots) on lawns of *E. coli* (gray background) expressing the indicated anti-CRISPR proteins and Type II-A, II-B and II-C Cas9-sgRNA programmed to target phage DNA. Representative pictures of at least 3 biological replicates are shown. (D) Gene editing activities of SpyCas9 and CjeCas9 in human cells in the presence of AcrIIA1 variants and orthologues. Control inhibitors (references in Methods): AcrIIA4 selective inhibitor of SpyCas9; AcrIIA5 broad-spectrum Cas9 inhibitor; AcrVA1 Cas12 inhibitor (negative control for Cas9 orthologues). Editing assessed by targeted sequencing. NT indicates a no-sgRNA control condition. Error bars indicate SEM for three independent biological replicates. See Figure S5C for editing experiments with additional Cas9 orthologues.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
rabbit anti-FLAG	Sigma-Aldrich	Cat# F7425; RRID: AB_439687
mouse anti-FLAG	Sigma-Aldrich	Cat# F1804; RRID: AB_262044
mouse anti-Myc	Cell Signaling Technology	Cat# 2276; RRID: AB_331783
rabbit anti-GST	Cell Signaling Technology	Cat# 2625; RRID: AB_490796
mouse anti- <i>E.coli</i> RNA polymerase β	BioLegend	Cat# 663903; RRID: AB_2564524
HRP-conjugated goat anti-Rabbit IgG	Bio-Rad	Cat# 170-6515; RRID: AB_11125142
HRP-conjugated goat anti-mouse IgG	Santa Cruz Biotechnology	Cat# sc-2005; RRID: AB_631736
Bacterial and Virus Strains		
<i>Listeria monocytogenes</i> 10403s	Rauch et al., 2017	RefSeq: NC_017544.1
<i>Listeria monocytogenes</i> 10403s derivatives	This paper	See Table S2
<i>Listeria ivanovii</i> WSLC 30167	Hupfeld et al., 2018	RefSeq: NZ_CP009575.1
<i>Listeria ivanovii</i> WSLC 3009	Hupfeld et al., 2018	RefSeq: NZ_CP007172.1
<i>Listeria monocytogenes</i> Mack	Hupfeld et al., 2018	https://doi.org/10.1093/nar/gky544
<i>Pseudomonas aeruginosa</i> strain PAO1	Laboratory of Alan Davidson	RefSeq: NC_002516.2
<i>Pseudomonas aeruginosa</i> strain PAO1 derivatives	This paper	N/A
<i>Escherichia coli</i> DH5 α	New England Biolabs	Cat #C29821
<i>E. coli</i> Rosetta (DE3) pLysS	QB3 Macrolab	N/A
<i>Escherichia coli</i> SM10	Laboratory of Daniel Portnoy	N/A
<i>E. coli</i> BB101	Garcia et al., 2019	https://doi.org/10.1016/j.celrep.2019.10.017
<i>Listeria</i> phage A006	This paper	RefSeq: NC_009815.1
<i>Listeria</i> phage A006 derivatives	This paper	See Table S2
<i>Listeria</i> phage A118	This paper	RefSeq: NC_003216.1
<i>Listeria</i> phage J0161a	Rauch et al., 2017	RefSeq: NC_017545.1
<i>Listeria</i> phage A511	Hupfeld et al., 2018	RefSeq: NC_009811.2
<i>Listeria</i> phages P35	This paper	RefSeq: NC_009814.1

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<i>Pseudomonas</i> phage JBD30	Laboratory of Alan Davidson	RefSeq; NC_020198.1
Phage Mu	Garcia et al., 2019	https://doi.org/10.1016/j.celrep.2019.10.017
Chemicals, Peptides, and Recombinant Proteins		
AcrIIA1 protein homologs tested for Cas9 inhibition	This paper	See Table S1
Purified protein: SpyCas9	QB3 Macrolab	N/A
Purified protein: 6xHis-MBP-SpyCas9	This paper	N/A
Purified protein: 6xHis-MBP-deadSpyCas9	This paper	N/A
Purified protein: 6xHis-MBP-SpyCas9(D10A)	This paper	N/A
Purified protein: 6xHis-MBP-SpyCas9(H840A)	This paper	N/A
Purified protein: 6xHis-AcrIIA1	This paper	N/A
Purified protein: 6xHis-AcrIIA1(T16A)	This paper	N/A
Purified protein: 6xHis-AcrIIA1(T114A/F115A)	This paper	N/A
Purified protein: 6xHis-AcrIIA1(F115A)	This paper	N/A
Purified protein: GST-AcrIIA1	This paper	N/A
Purified protein: GST-AcrIIA2b.3	This paper	N/A
Monolith His-Tag Labeling Kit RED-tris-NTA	Nanotemper Technologies	Cat #MO-L018
Monolith NT Protein Labeling kit RED-NHS	Nanotemper Technologies	Cat # L001
Tetrazolium Violet	TCI Chemicals	Cat #T0174
Critical Commercial Assays		
Gibson Assembly Master Mix	New England Biolabs	Cat #E2611L
Phusion Hot Start Flex DNA Polymerase	New England Biolabs	Cat #M0535S
TURBO DNA-free Kit	Thermo Fisher Scientific	Cat #AM1907
Luna Universal One-Step RT-qPCR Kit	New England Biolabs	Cat #E3005S
Myc-Tag Magnetic Bead Conjugate	Cell Signaling Technology	Cat #5698
Glutathione Magnetic Agarose Beads	Thermo Fisher Scientific	Cat #78601
4–20% Mini-PROTEAN TGX gels	Bio-Rad	Cat #4561096
Experimental Models: Cell Lines		
Human: HEK 293T cells	ATCC	ATCC CRL-11268
Oligonucleotides		
RT qPCR primer cas9-FWD: ATGCCGCGATAGATGGTTAC	This paper	N/A
RT qPCR primer cas9-REV: CGCCTTCGATGTTCTCCAATA	This paper	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
RT qPCR primer 16s-FWD: CCTGGTAGTCCACGCCGT	This paper	N/A
RT qPCR primer 16s-REV: TGC GTTAGCTGCAGCACTAAG	This paper	N/A
Target DNA used in SpyCas9-Acr <i>in vitro</i> binding assays CTCAGCCTGGAAGAGATCGTAACGCGAACTACGCGGTTGGTATACCAACATCATGACCT	This paper	N/A
oligonucleotides used in human cell experiments	This paper	See Table S4
Recombinant DNA		
pKSV7	Rauch et al., 2017	addgene.org/26686/
pKSV7-derivative plasmids	This paper	See Table S2
pPL2oexL	Rauch et al., 2017	https://doi.org/10.1016/j.cell.2016.12.009
pPL2oexL-derivative plasmids	This paper	See Table S2
pLEB579	Beasley et al., 2004	https://doi.org/10.1093/ps/83.1.45
pLEB579-derivative plasmids	This paper	See Table S2
pLRSR-crRNA plasmid	Hupfeld et al., 2018	https://doi.org/10.1093/nar/gky544
pHERD30T	Laboratory of Alan Davidson	GenBank: EU603326.1
pHERD30T-derivative plasmids	This paper	N/A
pMMB67HE	ATCC	http://www.snapgene.com/resources/plasmid_files/basic_cloning_vectors/pMMB67HE/
pMMB67HE-derivative plasmids	This paper	N/A
6xHis-MBP-SpyCas9 protein expression plasmid	Laboratory of Jennifer Doudna	N/A
6xHis-MBP-deadSpyCas9 protein expression plasmid	Laboratory of Jennifer Doudna	N/A
6xHis-MBP-SpyCas9(D10A) protein expression plasmid	Laboratory of Jennifer Doudna	N/A
6xHis-MBP-SpyCas9(H840A) protein expression plasmid	Laboratory of Jennifer Doudna	N/A
pET28 protein expression plasmid	Laboratory of David Morgan	N/A
pET28–6xHis-AcrIIA1 protein expression plasmid	This paper	N/A
pET28–6xHis-AcrIIA1(T16A) protein expression plasmid	This paper	N/A
pET28–6xHis-AcrIIA1(T114A/F115A) protein expression plasmid	This paper	N/A
pET28–6xHis-AcrIIA1(F115A) protein expression plasmid	This paper	N/A
pGEX-6P-1-GST-AcrIIA1 protein expression plasmid	This paper	N/A
pGEX-6P-1-GST-AcrIIA2b.3 protein expression plasmid	This paper	N/A
Type II-A, II-B, II-C Cas9-sgRNA plasmids in <i>E. coli</i>	Garcia et al., 2019	https://doi.org/10.1016/j.celrep.2019.10.017
Nuclease plasmids used in human cell experiments	This paper	See Table S3

REAGENT or RESOURCE	SOURCE	IDENTIFIER
sgRNA plasmids used in human cell experiments	This paper	See Table S3
Acr plasmids used in human cell experiments	This paper	See Table S3
Software and Algorithms		
Prism 6.0	GraphPad	https://www.graphpad.com/scientific-software/prism/
Gen 5	BioTek	https://www.biotek.com/products/software-robotics-software/gen5-microplate-reader-and-imager-software/
Image Lab 5.2.1	BioRad	http://bio-rad.com/en-cn/product/image-lab-software
NanoTemper Analysis Software	NanoTemper Technologies	https://nanotempertech.com/monolith/
CRISPResso2	Clement et al., 2019	http://crispresso.pinellolab.partners.org/
Other		
Synergy H1 Microplate Reader	BioTek	https://www.biotek.com/products/detection-hybrid-technology-multi-mode-microplate-readers/synergy-h1-hybrid-multi-mode-reader/
Azure c600 Imager	Azure Biosystems	https://www.azurebiosystems.com/imaging-systems/azure-600/
Monolith NT.115	NanoTemper Technologies	https://nanotempertech.com/monolith/
CFX Real-Time PCR Detection System	BioRad	https://www.bio-rad.com/en-us/product/cfx-connect-real-time-pcr-detection-system